CDK9 and cancer: We also found that SETD2-deficient cancer cells were more sensitive to transcriptional inhibitors, including the CDK9 inhibitor dinaciclib, which is in accordance with the notion that SETD2 loss–induced upregulation of oncogenic transcriptional programs is required for tumor maintenance.